Endothelial progenitor cell-based therapy for hemophilia A

International Journal of Hematology

Volumn 95, Issue 2, 2012, Pages 119-124

  Matsui, Hideto ^a  

^a NARA MEDICAL UNIVERSITY   (Japan)

Author keywords

Blood outgrowth endothelial progenitor cells; Ex vivo gene therapy; Hemophilia A

Indexed keywords

BLOOD CLOTTING FACTOR 8; CYCLOPHOSPHAMIDE;

ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BLOOD CLOTTING FACTOR 8 GENE; CELL COUNT; CELL DIFFERENTIATION; ENDOTHELIAL PROGENITOR CELL; GENE DELIVERY SYSTEM; GENE EXPRESSION; GENE TARGETING; GENE TRANSFER; HEMOPHILIA A; HUMAN; IMMUNE RESPONSE; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; NONVIRAL GENE THERAPY; SKIN FIBROBLAST; SOMATIC GENE THERAPY; TRANSGENE; VIRAL GENE THERAPY; ANIMAL; CYTOLOGY; ENDOTHELIUM CELL; GENE THERAPY; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; METHODOLOGY; MOUSE; MOUSE MUTANT; REVIEW;

ANIMALS; ENDOTHELIAL CELLS; FACTOR VIII; GENE THERAPY; GENE TRANSFER TECHNIQUES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMOPHILIA A; HUMANS; MICE; MICE, MUTANT STRAINS;

EID: 84862692478     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-012-1015-z     Document Type: Article

References (33)

1. Hoyer LW. Hemophilia A. N Engl J Med. 1994;330:38-47. (Pubitemid 24018616)
2. Levine PH. Clinical manifestation and therapy of hemophilias A and B. In: Coloman RW, Hirsh J, Marder VJ, Salzman EW, editors. Hemostasis and Thrombosis: basic principles and clinical practice. Philadelphia: Lippincott, J.B; 1987. p. 97-111.
3. Boloton-Maggs PH, Pasi KJ. Haemophilias A and B. Lancet. 2003;361:1801-9. (Pubitemid 36638432)
4. Valentino LA, Ewenstein B, Navickis RJ, Wilkes MM. Central venous access devices in hemophilia. Haemophilia. 2004;10: 134-46. (Pubitemid 38312640)
5. Brooker M. The World Federation of Hemophilia's third global forum on the Safety and Supply of Hemophilia Treatment Products, 22-23 September 2003, Budapest, Hungary. Haemophilia. 2004;10:290-4.
6. Jones P, Robillard L. The World Federation of Hemophilia: 40 years of improving hemophilia care worldwide. Haemophilia. 2003;9:663-9. (Pubitemid 37540805)
7. Blanchette VS, Manco-Johnson M, Santagostino E, Ljung R. Optimizing factor prophylaxis for the hemophilia population: where do we stand? Haemophilia. 2004;10(Suppl 4):97-104. (Pubitemid 40045427)
8. Mannucci PM, Tuddenham EG. The hemophilias-from royal genes to gene therapy. N Engl J Med. 2001;344:1773-9. (Pubitemid 32497033)
9. Giles AR, Tinlin S, Greenwood R. A canine model of hemophilic (factor VIII:C deficiency) bleeding. Blood. 1982;60:727.
10. Hough C, Kamisue S, Cameron C, et al. Aberrant splicing and premature termination of transcription of the FVIII gene as a cause of severe hemophilia A: similarities with the intron 22 inversion mutation in human hemophilia. Thromb Haemost. 2002;87:659-65. (Pubitemid 34302955)
11. Cameron C, Notley C, Hoyle S, et al. The canine factor VIII cDNA and 50 flanking sequence. Thromb Haemost. 1998;79: 317-22. (Pubitemid 28065877)
12. Notley C, Kiloran A, Cameron C, Wynd K, Hough C, Lillicrap D. The canine FVIII 30-untranslated region and a concatemeric hepatocyte nuclear factor 1 regulatory element enhance factor VIII transgene expression in vivo. Hum Gene Ther. 2002;13:1583-93. (Pubitemid 35034678)
13. Rawle FE, Lillicrap D. Preclinical animal models for hemophilia gene therapy: predictive value and limitations. Semin Thromb Haemost. 2004;30:205-13. (Pubitemid 38582324)
14. Brown BD, Shi CX, Powell S, Hurlbut D, Graham FL, Lillicrap D. Helper-dependent adenoviral vectors mediate therapeutic factor VIII expression for several months with minimal accompanying toxicity in a canine model of severe hemophilia A. Blood. 2004;103:804-10. (Pubitemid 38129536)
15. Chao H, Mansfield SG, Bartel RC, et al. Phenotype correction of hemophilia A mice by spliceosome-mediated RNA trans-splicing. Nat Med. 2003;9:1015-9. (Pubitemid 37025113)
16. Chuah MK, Schiedner G, Thorrez L, et al. Therapeutic factor VIII levels and negligible toxicity in mouse and dog models of hemophilia A following gene therapy with high-capacity adenoviral vectors. Blood. 2003;101:1734-43. (Pubitemid 36237568)
17. Connelly S, Andrews JL, Gallo AM, et al. Sustained phenotypic correction of murine hemophilia A by in vivo gene therapy. Blood. 1998;91:3273-81. (Pubitemid 28193877)
18. Dwarki VJ, Belloni P, Nijjar T, et al. Gene therapy for hemophilia A: production of therapeutic levels of human factor VIII in vivo in mice. Proc Natl Acad Sci USA. 1995;92:1023-7.
19. Gallo-Penn AM, Shirley PS, Andrew JL, et al. In vivo evaluation of an adenoviral vector encoding canine factor VIII: high-level, sustained expression in hemophilia mice. Hum Gene Ther. 1999;10:1791-802. (Pubitemid 29357685)
20. Kay MA, Rorhenberg S, Landen CN, et al. In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient dogs. Science. 1993;262:117-9.
21. Sarkar R, Tetreault R, Gao G, et al. Total correction of hemophilia a mice with canine FVIII using an AAV 8 serotype. Blood. 2004;103:1253-60. (Pubitemid 38168635)
22. Scallan CD, Lillicrap D, Jiang H, et al. Sustained phenotypic correction of canine hemophilia A using an adeno-associated viral vector. Blood. 2003;102:2031-7. (Pubitemid 37122376)
23. Matsui H, Shibata M, Brown B, et al. A murine model for induction of long-term immunologic tolerance to factor VIII does not require persistent detectable levels of plasma factor VIII and involves contributions from Foxp3? T regulatory cells. Blood. 2009;114:677-85.
24. Matsui H, Hegadorn C, Ozelo M, et al. A microRNA-regulated and GP64-pseudotyped lentiviral vector mediates stable expression of FVIII in a murine model of hemophilia A. Mol Ther. 2011;19:723-30.
25. Roth DA, Tawa NE Jr, O'Brien JM, Treco DA, Selden RF. Nonviral transfer of the gene encoding coagulation factor VIII in patients with severe hemophilia A. N Engl J Med. 2001;344: 1735-42. (Pubitemid 32497027)
26. Powell JS, Ragni MV, White GC, et al. Phase 1 trial of FVIII gene transfer for severe hemophilia A using a retroviral construct administrated by peripheral intravenous infusion. Blood. 2003;102:2038-45. (Pubitemid 37122377)
27. Manno CS, Chew AJ, Hutchinson S, et al. AAV-mediated factor IX gene transfer to skeletal muscle in patients with severe hemophilia B. Blood. 2003;101:2963-72. (Pubitemid 36857981)
28. Brown BD, Lillicrap D. Dangerous liaisons: the role of "danger" signals in the immune response to gene therapy. Blood. 2002;100:1133-40.
29. Kaiser J. Gene therapy. Side effects sideline hemophilia trial. Science. 2004;304:1423-5.
30. Hacein-Bey-Abina S, Von Kalle C, Schmidt M, et al. LMO2- associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. Science. 2003;302:415-9. (Pubitemid 37296260)
31. Matsui H, Shibata M, Brown B, et al. Ex vivo gene therapy for hemophilia A that enhances safe delivery and sustained in vivo factor VIII expression from lentivirally engineered endothelial progenitors. Stem Cells. 2007;25:2660-9. (Pubitemid 47582759)
32. Lin Y, Weisdorf DJ, Solovey A, Hebbel RP. Origins of circulating endothelial cells and endothelial outgrowth from blood. J Clin Invest. 2000;105:71-7. (Pubitemid 30036389)
33. Koppelman SJ, van Hoeij M, Vink T, et al. Requirements of von Willebrand factor to protect factor VIII inactivation by activated protein C. Blood. 1996;87:2292-300. (Pubitemid 26086869)